Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 537

1.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.

PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.

2.

Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses.

Chissumba RM, Luciano A, Namalango E, Bauer A, Bhatt N, Wahren B, Nilsson C, Geldmacher C, Scarlatti G, Jani I, Kestens L; TaMoVac II group.

Immunobiology. 2018 Dec;223(12):792-801. doi: 10.1016/j.imbio.2018.08.006. Epub 2018 Aug 12.

PMID:
30121146
3.

DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response.

Petkov S, Starodubova E, Latanova A, Kilpeläinen A, Latyshev O, Svirskis S, Wahren B, Chiodi F, Gordeychuk I, Isaguliants M.

PLoS One. 2018 Jun 4;13(6):e0197902. doi: 10.1371/journal.pone.0197902. eCollection 2018.

4.

Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.

Latanova AA, Petkov S, Kilpelainen A, Jansons J, Latyshev OE, Kuzmenko YV, Hinkula J, Abakumov MA, Valuev-Elliston VT, Gomelsky M, Karpov VL, Chiodi F, Wahren B, Logunov DY, Starodubova ES, Isaguliants MG.

Sci Rep. 2018 May 24;8(1):8078. doi: 10.1038/s41598-018-26281-z.

5.

Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

Viegas EO, Tembe N, Nilsson C, Meggi B, Maueia C, Augusto O, Stout R, Scarlatti G, Ferrari G, Earl PL, Wahren B, Andersson S, Robb ML, Osman N, Biberfeld G, Jani I, Sandström E.

AIDS Res Hum Retroviruses. 2018 Feb;34(2):193-205. doi: 10.1089/AID.2017.0121. Epub 2017 Nov 27.

PMID:
28969431
6.

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.

Hinkula J, Petkov S, Ljungberg K, Hallengärd D, Bråve A, Isaguliants M, Falkeborn T, Sharma S, Liakina V, Robb M, Eller M, Moss B, Biberfeld G, Sandström E, Nilsson C, Markland K, Blomberg P, Wahren B.

Heliyon. 2017 Jun 29;3(6):e00339. doi: 10.1016/j.heliyon.2017.e00339. eCollection 2017 Jun.

7.

Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.

Bauer A, Podola L, Mann P, Missanga M, Haule A, Sudi L, Nilsson C, Kaluwa B, Lueer C, Mwakatima M, Munseri PJ, Maboko L, Robb ML, Tovanabutra S, Kijak G, Marovich M, McCormack S, Joseph S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Bakari M, Kroidl A, Geldmacher C.

J Virol. 2017 Aug 24;91(18). pii: e00730-17. doi: 10.1128/JVI.00730-17. Print 2017 Sep 15.

8.

Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.

Stenler S, Lundin KE, Hansen L, Petkov S, Mozafari N, Isaguliants M, Blomberg P, Smith CIE, Goldenberg DM, Chang CH, Ljungberg K, Hinkula J, Wahren B.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2849-2858. doi: 10.1080/21645515.2017.1338546. Epub 2017 Jul 11.

9.

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.

Joachim A, Munseri PJ, Nilsson C, Bakari M, Aboud S, Lyamuya EF, Tecleab T, Liakina V, Scarlatti G, Robb ML, Earl PL, Moss B, Wahren B, Mhalu F, Ferrari G, Sandstrom E, Biberfeld G.

AIDS Res Hum Retroviruses. 2017 Aug;33(8):880-888. doi: 10.1089/AID.2016.0251. Epub 2017 Jan 27.

10.

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.

Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, Missanga M, Mann P, Wahren B, Ferrari G, Polonis VR, Robb ML, Weber J, Tatoud R, Maboko L, Hoelscher M, Lyamuya EF, Biberfeld G, Sandström E, Kroidl A, Bakari M, Nilsson C, McCormack S.

PLoS One. 2016 May 18;11(5):e0155702. doi: 10.1371/journal.pone.0155702. eCollection 2016.

11.

The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children.

Palma P, Foster C, Rojo P, Zangari P, Yates A, Cotugno N, Klein N, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, Borkowsky W, Bernardi S, Calvez V, Manno E, Mora N, Compagnucci A, Wahren B, Muñoz-Fernández M, De Rossi A, Ananworanich J, Pillay D, Giaquinto C, Rossi P.

J Virus Erad. 2015;1(3):134-139. Epub 2015 Jun 30.

12.

Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission.

Klein N, Palma P, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, Rojo P, Borkowsky W, Bernardi S, Zangari P, Calvez V, Compagnucci A, Wahren B, Foster C, Munoz-Fernández MÁ, De Rossi A, Ananworanich J, Pillay D, Giaquinto C, Rossi P.

Lancet Infect Dis. 2015 Sep;15(9):1108-1114. doi: 10.1016/S1473-3099(15)00052-3. Epub 2015 Jul 14.

PMID:
26187030
13.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, Earl PL, Stout RR, Robb ML, Shattock RJ, Biberfeld G, Sandström E, Wahren B.

PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.

14.

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, Moshiro C, Aboud S, Lyamuya E, Maboko L, Missanga M, Kaluwa B, Mfinanga S, Podola L, Bauer A, Godoy-Ramirez K, Marovich M, Moss B, Hoelscher M, Gotch F, Stöhr W, Stout R, McCormack S, Wahren B, Mhalu F, Robb ML, Biberfeld G, Sandström E, Bakari M.

PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629. eCollection 2015.

15.

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.

Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, Marovich MA, Earl P, Moss B, Ochsenbauer C, Wahren B, Mhalu F, Sandström E, Biberfeld G, Ferrari G, Polonis VR.

PLoS One. 2015 Apr 14;10(4):e0118486. doi: 10.1371/journal.pone.0118486. eCollection 2015.

16.

Short communication: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa.

Kilpeläinen A, Axelsson Robertson R, Leitner T, Sandström E, Maeurer M, Wahren B.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1065-71. doi: 10.1089/AID.2013.0299. Epub 2014 Jul 16.

17.

Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression.

Stenler S, Wiklander OP, Badal-Tejedor M, Turunen J, Nordin JZ, Hallengärd D, Wahren B, Andaloussi SE, Rutland MW, Smith CI, Lundin KE, Blomberg P.

Mol Ther Nucleic Acids. 2014 Jan 7;2:e140. doi: 10.1038/mtna.2013.67.

18.

Immunotherapy with an HIV-DNA Vaccine in Children and Adults.

Palma P, Gudmundsdotter L, Finocchi A, Eriksson LE, Mora N, Santilli V, Aquilani A, Manno EC, Zangari P, Romiti ML, Montesano C, Grifoni A, Brave A, Ljungberg K, Blomberg P, Bernardi S, Sandström E, Hejdeman B, Rossi P, Wahren B.

Vaccines (Basel). 2014 Jul 17;2(3):563-80. doi: 10.3390/vaccines2030563.

19.

Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC).

Palma P, Romiti ML, Montesano C, Santilli V, Mora N, Aquilani A, Dispinseri S, Tchidjou HK, Montano M, Eriksson LE, Baldassari S, Bernardi S, Scarlatti G, Wahren B, Rossi P.

PLoS One. 2013 Nov 28;8(11):e79957. doi: 10.1371/journal.pone.0079957. eCollection 2013.

20.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

21.

Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness.

Nowroozalizadeh S, Gudmundsdotter L, Hejdeman B, Andersson L, Esbjörnsson J, Medstrand P, Sandström E, Gaines H, Wahren B, Jansson M.

Hum Vaccin Immunother. 2013 Oct;9(10):2103-10. doi: 10.4161/hv.25154. Epub 2013 Jun 4.

22.

Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme's performance in gene immunization.

Isaguliants M, Smirnova O, Ivanov AV, Kilpelainen A, Kuzmenko Y, Petkov S, Latanova A, Krotova O, Engström G, Karpov V, Kochetkov S, Wahren B, Starodubova E.

Hum Vaccin Immunother. 2013 Oct;9(10):2111-9. doi: 10.4161/hv.25813. Epub 2013 Jul 23.

23.

A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity.

Hallengärd D, Wahren B, Bråve A.

Viral Immunol. 2013 Apr;26(2):163-6. doi: 10.1089/vim.2012.0083.

PMID:
23573980
24.

Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses.

Hallengärd D, Applequist SE, Nyström S, Maltais AK, Marovich M, Moss B, Earl P, Nihlmark K, Wahren B, Bråve A.

Viral Immunol. 2012 Oct;25(5):423-32. doi: 10.1089/vim.2012.0046.

PMID:
23035853
25.

A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines.

Hallengärd D, Bråve A, Isaguliants M, Blomberg P, Enger J, Stout R, King A, Wahren B.

Genet Vaccines Ther. 2012 Aug 8;10(1):5. doi: 10.1186/1479-0556-10-5.

26.

A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.

Chang CH, Hinkula J, Loo M, Falkeborn T, Li R, Cardillo TM, Rossi EA, Goldenberg DM, Wahren B.

PLoS One. 2012;7(7):e41235. doi: 10.1371/journal.pone.0041235. Epub 2012 Jul 23.

27.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.

Ruffin N, Borggren M, Euler Z, Fiorino F, Grupping K, Hallengärd D, Javed A, Mendonca K, Pollard C, Reinhart D, Saba E, Sheik-Khalil E, Sköld A, Ziglio S, Scarlatti G, Gotch F, Wahren B, Shattock RJ.

J Transl Med. 2012 Jul 11;10:144. doi: 10.1186/1479-5876-10-144.

28.

Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.

Buonaguro L, Tagliamonte M, Visciano ML, Andersen H, Lewis M, Pal R, Tornesello ML, Schroeder U, Hinkula J, Wahren B, Buonaguro FM.

Clin Vaccine Immunol. 2012 Jun;19(6):970-3. doi: 10.1128/CVI.00068-12. Epub 2012 Mar 29.

29.

Induction of IgM, IgA and IgE antibodies in colorectal cancer patients vaccinated with a recombinant CEA protein.

Staff C, Magnusson CG, Hojjat-Farsangi M, Mosolits S, Liljefors M, Frödin JE, Wahrén B, Mellstedt H, Ullenhag GJ.

J Clin Immunol. 2012 Aug;32(4):855-65. doi: 10.1007/s10875-012-9662-7. Epub 2012 Mar 2.

PMID:
22382876
30.

Receptor Binding by Cholera Toxin B-Subunit and Amino Acid Modification Improves Minimal Peptide Immunogenicity.

Boberg A, Stålnacke A, Bråve A, Hinkula J, Wahren B, Carlin N.

ISRN Mol Biol. 2012 Jul 15;2012:170676. doi: 10.5402/2012/170676. eCollection 2012.

31.

Accumulation and activation of natural killer cells in local intraperitoneal HIV-1/MuLV infection results in early control of virus infected cells.

Johansson SE, Brauner H, Hinkula J, Wahren B, Berg L, Johansson MH.

Cell Immunol. 2011;272(1):71-8. doi: 10.1016/j.cellimm.2011.09.005. Epub 2011 Sep 22.

PMID:
22019129
32.

NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.

Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, Hinkula J, Wahren B, Kärre K, Kent SJ, Berg L.

Viral Immunol. 2011 Oct;24(5):359-68. doi: 10.1089/vim.2011.0025. Epub 2011 Sep 29.

PMID:
21958370
33.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Bråve A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E.

Vaccine. 2011 Oct 26;29(46):8417-28. doi: 10.1016/j.vaccine.2011.08.001. Epub 2011 Aug 22.

34.

Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).

Onyango-Makumbi C, Omer SB, Mubiru M, Moulton LH, Nakabiito C, Musoke P, Mmiro F, Zwerski S, Wigzell H, Falksveden L, Wahren B, Antelman G, Fowler MG, Guay L, Jackson JB.

J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):399-407. doi: 10.1097/QAI.0b013e31822f8914.

35.

Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation.

Hallengärd D, Haller BK, Maltais AK, Gelius E, Nihlmark K, Wahren B, Bråve A.

Clin Vaccine Immunol. 2011 Sep;18(9):1577-81. doi: 10.1128/CVI.05045-11. Epub 2011 Jul 13.

36.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.

Brinckmann S, da Costa K, van Gils MJ, Hallengärd D, Klein K, Madeira L, Mainetti L, Palma P, Raue K, Reinhart D, Reudelsterz M, Ruffin N, Seifried J, Schäfer K, Sheik-Khalil E, Sköld A, Uchtenhagen H, Vabret N, Ziglio S, Scarlatti G, Shattock R, Wahren B, Gotch F.

J Transl Med. 2011 Apr 12;9:40. doi: 10.1186/1479-5876-9-40.

37.

Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.

Gudmundsdotter L, Wahren B, Haller BK, Boberg A, Edbäck U, Bernasconi D, Buttò S, Gaines H, Imami N, Gotch F, Lori F, Lisziewicz J, Sandström E, Hejdeman B.

Vaccine. 2011 Jul 26;29(33):5558-66. doi: 10.1016/j.vaccine.2011.01.064. Epub 2011 Feb 5.

PMID:
21300092
38.

The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.

Palma P, Romiti ML, Li Pira G, Montesano C, Mora N, Aquilani A, Santilli V, Tchidjou HK, Ivaldi F, Giovannelli L, Pontrelli G, Borra G, Blomberg P, Gudmundsdotter L, Bråve A, Montano M, Bernardi S, Manca F, Wahren B, Rossi P.

Vaccine. 2011 Sep 9;29(39):6810-6. doi: 10.1016/j.vaccine.2010.12.058. Epub 2011 Jan 7.

PMID:
21216310
39.

A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients.

Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M.

Vaccine. 2011 Sep 9;29(39):6817-22. doi: 10.1016/j.vaccine.2010.12.063. Epub 2010 Dec 30.

PMID:
21195077
40.

Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity.

Hallengärd D, Haller BK, Petersson S, Boberg A, Maltais AK, Isaguliants M, Wahren B, Bråve A.

Vaccine. 2011 Jan 17;29(4):839-48. doi: 10.1016/j.vaccine.2010.10.083. Epub 2010 Nov 23.

PMID:
21109032
41.

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation.

Bråve A, Gudmundsdotter L, Sandström E, Haller BK, Hallengärd D, Maltais AK, King AD, Stout RR, Blomberg P, Höglund U, Hejdeman B, Biberfeld G, Wahren B.

Vaccine. 2010 Nov 29;28(51):8203-9. doi: 10.1016/j.vaccine.2010.08.108. Epub 2010 Oct 15.

PMID:
20951666
42.

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.

Wahren B, Biswas P, Borggren M, Coleman A, Da Costa K, De Haes W, Dieltjens T, Dispinseri S, Grupping K, Hallengärd D, Hornig J, Klein K, Mainetti L, Palma P, Reudelsterz M, Seifried J, Selhorst P, Sköld A, Uchtenhagen H, van Gils MJ, Weber C, Shattock R, Scarlatti G.

J Transl Med. 2010 Jul 26;8:72. doi: 10.1186/1479-5876-8-72. Erratum in: J Transl Med. 2010;8(1):82. Uchtenhagen, Hannes [added].

43.

Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.

Aboud S, Nilsson C, Karlén K, Marovich M, Wahren B, Sandström E, Gaines H, Biberfeld G, Godoy-Ramirez K.

Clin Vaccine Immunol. 2010 Jul;17(7):1124-31. doi: 10.1128/CVI.00008-10. Epub 2010 May 12.

44.

Potent cross-reactive immune response against the wild-type and drug-resistant forms of HIV reverse transcriptase after the chimeric gene immunization.

Starodubova E, Boberg A, Ivanov A, Latyshev O, Petrakova N, Kuzmenko Y, Litvina M, Chernousov A, Kochetkov S, Karpov V, Wahren B, Isaguliants MG.

Vaccine. 2010 Feb 23;28(8):1975-86. doi: 10.1016/j.vaccine.2009.10.098.

PMID:
20188253
45.

Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes.

Brave A, Johansson U, Hallengärd D, Heidari S, Gullberg H, Wahren B, Hinkula J, Spetz AL.

Vaccine. 2010 Feb 25;28(9):2080-7. doi: 10.1016/j.vaccine.2009.12.040. Epub 2009 Dec 29.

PMID:
20044053
46.

NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients.

Johansson SE, Hejdeman B, Hinkula J, Johansson MH, Romagné F, Wahren B, Wagtmann NR, Kärre K, Berg L.

Clin Immunol. 2010 Feb;134(2):158-68. doi: 10.1016/j.clim.2009.10.001. Epub 2009 Nov 1.

PMID:
19880352
47.

Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment.

Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, Bråve A, Wahren B, Pisa P.

PLoS One. 2009 Sep 30;4(9):e7226. doi: 10.1371/journal.pone.0007226.

48.

Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.

Hinkula J, Walther-Jallow L, Laurén A, Mäkitalo B, Oberg M, Wahren B, Fenyö EM, Spetz AL.

Vaccine. 2009 Oct 30;27(46):6424-31. doi: 10.1016/j.vaccine.2009.06.016. Epub 2009 Jun 21.

PMID:
19549607
49.

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B.

Vaccine. 2009 Jul 16;27(33):4468-74. doi: 10.1016/j.vaccine.2009.05.018. Epub 2009 May 29.

50.

Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.

Bråve A, Hallengärd D, Gudmundsdotter L, Stout R, Walters R, Wahren B, Hallermalm K.

Vaccine. 2009 Jun 8;27(28):3692-6. doi: 10.1016/j.vaccine.2009.04.013. Epub 2009 May 3.

PMID:
19428161

Supplemental Content

Loading ...
Support Center